Literature DB >> 190264

Urinary excretion of cyclic 3',5'-adenosine monophosphate and cyclic 3',5'-guanosine monophosphate during and after pregnancy.

L Kopp, G Paradiz, J R Tucci.   

Abstract

Urinary cyclic AMP and cyclic GMP excretions were measured in 24-h urine specimens obtained from 89 women at various times during their normal uncomplicated intrauterine pregnancies and from 49 women at various times after the births of their normal healthy infants. Cyclic AMP excretion increased steadily from the beginning of the second trimester or earlier until late in the third trimester, reaching a peak excretion approximately 40% greater than that of normal nonpregnant women. The cyclic AMP excretion dropped abruptly by the first day after parturition to levels which were not significant different from those of normal non-pregnant women. In contrast, cyclic GMP excretion increased rapidly during the first trimester and remained relatively constant during the remainder of the pregnancy, reaching a peak excretion of about 140% greater than that of normal nonpregnant women. Furthermore, it decreased slowly toward normal levels, but was still significantly elevated six weeks after parturition. The factors responsible for the increased excretion of cyclic AMP during pregnancy and for the increased cyclic GMP during and after pregnancy are not known.

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 190264     DOI: 10.1210/jcem-44-3-590

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  11 in total

Review 1.  Impact of pregnancy on underlying renal disease.

Authors:  Chris Baylis
Journal:  Adv Ren Replace Ther       Date:  2003-01

2.  Hyperthyroidism and pregnancy.

Authors:  J R Tucci
Journal:  J Endocrinol Invest       Date:  1990-02       Impact factor: 4.256

Review 3.  Gap junction regulation of vascular tone: implications of modulatory intercellular communication during gestation.

Authors:  Bryan C Ampey; Timothy J Morschauser; Paul D Lampe; Ronald R Magness
Journal:  Adv Exp Med Biol       Date:  2014       Impact factor: 2.622

4.  Sildenafil Treatment Ameliorates the Maternal Syndrome of Preeclampsia and Rescues Fetal Growth in the Dahl Salt-Sensitive Rat.

Authors:  Ellen E Gillis; Jennifer N Mooney; Michael R Garrett; Joey P Granger; Jennifer M Sasser
Journal:  Hypertension       Date:  2016-01-04       Impact factor: 10.190

Review 5.  Emerging role of relaxin in the maternal adaptations to normal pregnancy: implications for preeclampsia.

Authors:  Kirk P Conrad
Journal:  Semin Nephrol       Date:  2011-01       Impact factor: 5.299

6.  Domain-Specific Partitioning of Uterine Artery Endothelial Connexin43 and Caveolin-1.

Authors:  Bryan C Ampey; Timothy J Morschauser; Jayanth Ramadoss; Ronald R Magness
Journal:  Hypertension       Date:  2016-08-29       Impact factor: 10.190

7.  Glycine rectifies vascular dysfunction induced by dietary protein imbalance during pregnancy.

Authors:  L Brawley; C Torrens; F W Anthony; S Itoh; T Wheeler; A A Jackson; G F Clough; L Poston; M A Hanson
Journal:  J Physiol       Date:  2003-10-24       Impact factor: 5.182

8.  Effect of cGMP on pharmacomechanical coupling in the uterine artery of near-term pregnant sheep.

Authors:  Lubo Zhang; Daliao Xiao; Xiangqun Hu
Journal:  J Pharmacol Exp Ther       Date:  2008-08-05       Impact factor: 4.030

9.  Functional and molecular characterization of endothelium-dependent and endothelium-independent relaxant pathways in uterine artery of non-pregnant buffaloes.

Authors:  Udayraj P Nakade; Abhishek Sharma; Priyambada Kumari; Shirish Bhatiya; Sooraj V Nair; K N Karikaran; Vipin Sharma; Soumen Choudhury; Satish Kumar Garg
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2019-09-07       Impact factor: 3.000

10.  The vasoconstrictor effects of L-NAME, a nitric oxide synthase inhibitor, in pregnant rabbits.

Authors:  G Losonczy; I Mucha; V Müller; T Kriston; Z Ungvári; L Tornóci; L Rosivall; R Venuto
Journal:  Br J Pharmacol       Date:  1996-06       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.